Chinese biopharma that in-licenses innovative drugs in nephrology, infectious disease and oncology for Greater China/Asia.
Chinese biopharma that in-licenses innovative drugs in nephrology, infectious disease and oncology for Greater China/Asia.
Pays licensors upfront fees, milestones and royalties for Greater China and some Asian rights, then earns from selling the drugs itself to hospitals, with Nefecon, a kidney-disease drug licensed from Calliditas, as the lead product. Each market's approvals and reimbursement listings set the volumes.
In one line: A Chinese in-licensing specialty pharma, similar to a smaller Zai Lab.
Moat: narrow (regulatory licence, distribution). Regional development and commercialization rights secured via licensing deals with global biotechs.
Headquarters: Shanghai, China · Founded: 2017 · Employees: 812
Size Everest Medicines (1952.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 574th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.44 on 18 Nov 2026.
Performance Over six months the shares fell 20.3%, against -8.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 192.6% over the last twelve months (peer median +2.4%); the operating margin is -5.3% (peer median 9.7%).
Valuation It trades at 23.2× forward earnings against a peer median of 14.5× (4th most expensive of 15).
Capital Return on invested capital runs 16.1 points below its cost of capital (14.1% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.69B | HK$1.85B | HK$766M | HK$139M | HK$14.9M |
| Revenue growth | — | +142% | +451% | +835% | — |
| Gross profit | HK$1.69B | HK$1.11B | HK$426M | HK$16.3M | -HK$40.3M |
| EBITDA | HK$40.7M | -HK$249M | -HK$681M | -HK$849M | -HK$1.58B |
| Net income | -HK$59.3M | -HK$323M | -HK$1.13B | -HK$933M | -HK$288M |
| Free cash flow | -HK$354M | -HK$192M | -HK$829M | -HK$988M | -HK$1.76B |
| Capital expenditure | HK$892M | HK$378M | HK$221M | HK$294M | HK$503M |
| Total debt | n/a | HK$1.03B | HK$612M | HK$593M | HK$124M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Everest Medicines 1952.HK | $1.05B | -20% | +193% | -5% | 23.2× | n/a |
| Zai Lab Ltd. Sponsored ADR ZLAB | $3.00B | +18% | 0% | -63% | n/a | n/a |
| China Medical System 0867.HK | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1952.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.7% | -4.7% | lowest of 21 |
| 6-month return | -20.3% | -8.7% | 5th lowest of 21 |
| Distance from 52-week high | -51.4% | -31.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +192.6% | +2.4% | highest of 18 |
| Operating margin | -5.3% | 9.7% | 4th lowest of 19 |
| Forward P/E | 23.2× | 14.5× | 4th most expensive of 15 |
| ROIC minus cost of capital | -16.1 pp | +0.2 pp | 3rd lowest of 19 |
| Net debt / EBITDA | -1.3× | -1.4× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |